Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

Eugènia Negredo; Anna Bonjoch; Roger Paredes; Jordi Puig; Bonaventura Clotet

doi:https://doi.org/10.1086/432879

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

Eugènia Negredo, Anna Bonjoch, Roger Paredes, Jordi Puig, Bonaventura Clotet

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

22 Citations (Scopus)

Abstract

The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. © 2005 by the Infectious Diseases Society of America. All rights reserved.

Original language	English
Pages (from-to)	901-905
Journal	Clinical Infectious Diseases
Volume	41
DOIs	https://doi.org/10.1086/432879
Publication status	Published - 15 Sep 2005

Access to Document

https://doi.org/10.1086/432879

Fingerprint Dive into the research topics of 'Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies'. Together they form a unique fingerprint.

Cite this

Negredo, E., Bonjoch, A., Paredes, R., Puig, J., & Clotet, B. (2005). Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clinical Infectious Diseases, 41, 901-905. https://doi.org/10.1086/432879

@article{bd22c71e04ef4e7db6b70adc3917da9b,

title = "Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies",

abstract = "The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. {\textcopyright} 2005 by the Infectious Diseases Society of America. All rights reserved.",

author = "Eug{\`e}nia Negredo and Anna Bonjoch and Roger Paredes and Jordi Puig and Bonaventura Clotet",

year = "2005",

month = sep,

day = "15",

doi = "https://doi.org/10.1086/432879",

language = "English",

volume = "41",

pages = "901--905",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

}

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. / Negredo, Eugènia; Bonjoch, Anna; Paredes, Roger; Puig, Jordi; Clotet, Bonaventura.

In: Clinical Infectious Diseases, Vol. 41, 15.09.2005, p. 901-905.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

AU - Negredo, Eugènia

AU - Bonjoch, Anna

AU - Paredes, Roger

AU - Puig, Jordi

AU - Clotet, Bonaventura

PY - 2005/9/15

Y1 - 2005/9/15

N2 - The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. © 2005 by the Infectious Diseases Society of America. All rights reserved.

AB - The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period. © 2005 by the Infectious Diseases Society of America. All rights reserved.

U2 - https://doi.org/10.1086/432879

DO - https://doi.org/10.1086/432879

M3 - Article

VL - 41

SP - 901

EP - 905

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -